Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2009

View Archived Issues

GW-3965 improves cognition in impaired mice

Tapentadol extended release shows efficacy and safety in phase III study of chronic pain

Phase I results for IVN-201 for cat dander allergy announced by ImVisioN

Vardenafil improves continence after prostatectomy; LUTS in benign prostatic hyperplasia patients

Shire voluntarily recalls Daytrana transdermal patch due to release liner defect

FDA approves Lexapro for major depressive disorder in adolescents

SkyePharma files NDA for Flutiform with the FDA

Merck Frosst Canada presents novel renin inhibitors

Allergan reports novel pyrrole compounds for the treatment of glaucoma

Clinical trial results for MB-07803 in type 2 diabetes reported by Metabasis

CHMP recommends marketing authorization for HRA's emergency contraceptive ellaOne

Novel clinical candidate for type 2 diabetes treatment described by Amgen

Novel histamine H3 receptor antagonist presented by Pfizer

Injection of adenovirus expressing SkM1 demonstrates antiarrhythmic activity

Micromet initiates phase II adecatumumab trial in colorectal cancer patients

Nereus Pharmaceuticals has begun a phase II trial of NPI-2358 in NSCLC

Transition initiates phase Ib TT-223/GLP-1 analogue study in type 2 diabetes

CHMP recommends marketing authorization for Astellas' Modigraf in transplant rejection

Oryzon acquires Crystax

NMRC submits revised IND to FDA to conduct RESUS clinical trial of Biopure's Hemopure

FDA approves Symbyax for treatment-resistant depression

Exalgo extended-release meets primary efficacy endpoint in phase III trial

Torii to launch Remitch in Japan for pruritus in hemodialysis

Vertex Pharmaceuticals claims novel protein kinase inhibitors

Roche presents novel pyrrolodine aryl-ether compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...